BIOAGE LABS INC
BIOANASDAQTrading Snapshot
- Day Range
- $5.82 – $6.25
- 52-Week Range
- $4.81 – $25.96
- Volume (shares)
- 844,083
- Avg Volume (shares)
- —
- Shares Outstanding
- 37.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $9M
- Last Q Revenue
- $2M
- P/E Ratio
- -2.5
- P/S Ratio
- 21.6x
- EPS (TTM)
- $-2.11
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.7%
BIOAGE LABS INC
BIOA
StockOtter · stockotter.spaceAbout BIOAGE LABS INC
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Origin's virtual scree
Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA
Bank of America Corp DE acquired a new position in shares of BioAge Labs, Inc. (NASDAQ: BIOA) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic dise
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript